Chun Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Chun Wang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Chengjie Xie
GMU‐GIBH Joint School of Life Sciences Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou Medical University Guangzhou P.R. China
1 shared publication - Feng-Hai Yu
GMU‐GIBH Joint School of Life Sciences Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou Medical University Guangzhou P.R. China
1 shared publication - Guoliang Lin
Department of Chemistry, Temple University, Philadelphia, Pennsylvania 19122
1 shared publication - Ke Ding
GMU‐GIBH Joint School of Life Sciences Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou Medical University Guangzhou P.R. China
1 shared publication - Lei Lu
GMU‐GIBH Joint School of Life Sciences Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou Medical University Guangzhou P.R. China
1 shared publication - Quanxin Li
GMU‐GIBH Joint School of Life Sciences Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou Medical University Guangzhou P.R. China
1 shared publication
Latest Publications
- Open Access
- 5 February 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (3) , e23449
G‐protein‐coupled estrogen receptor 1 promotes peritoneal metastasis of gastric cancer through nicotinamide adenine dinucleotide kinase 1‐mediated redox modulation
Adipose tissue is the second most important site of estrogen production, where androgens are converted into estrogen by aromatase. While gastric cancer patients often develop adipocyte‐rich peritoneal metastasis, the underlying mechanism remains unclear. In this study, we identified the G‐protein‐coupled estrogen receptor (GPER1) as a promoter of gastric cancer peritoneal metastasis. Functional in vitro studies revealed that β‐Estradiol (E2) or the GPER1 agonist G1 inhibited anoikis in gastric cancer cells. Additionally, genetic overexpression or knockout of GPER1 significantly inhibited or enhanced gastric cancer cell anoikis in vitro and peritoneal metastasis in vivo, respectively. Mechanically, GPER1 knockout disrupted the NADPH pool and increased reactive oxygen species (ROS) generation. Conversely, overexpression of GPER1 had the opposite effects. GPER1 suppressed nicotinamide adenine dinucleotide kinase 1(NADK1) ubiquitination and promoted its phosphorylation, which were responsible for the elevated expression of NADK1 at protein levels and activity, respectively. Moreover, genetic inhibition of NADK1 disrupted NADPH and redox homeostasis, leading to high levels of ROS and significant anoikis, which inhibited lung and peritoneal metastasis in cell‐based xenograft models. In summary, our study suggests that inhibiting GPER1‐mediated NADK1 activity and its ubiquitination may be a promising therapeutic strategy for peritoneal metastasis of gastric cancer.
- 5 February 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (3) , e23449
Open AccessG‐protein‐coupled estrogen receptor 1 promotes peritoneal metastasis of gastric cancer through nicotinamide adenine dinucleotide kinase 1‐mediated redox modulation
Adipose tissue is the second most important site of estrogen production, where androgens are converted into estrogen by aromatase. While gastric cancer patients often develop adipocyte‐rich peritoneal metastasis, the underlying mechanism remains unclear. In this study, we identified the G‐protein‐coupled estrogen receptor (GPER1) as a promoter of gastric cancer peritoneal metastasis. Functional in vitro studies revealed that β‐Estradiol (E2) or the GPER1 agonist G1 inhibited anoikis in gastric cancer cells. Additionally, genetic overexpression or knockout of GPER1 significantly inhibited or enhanced gastric cancer cell anoikis in vitro and peritoneal metastasis in vivo, respectively. Mechanically, GPER1 knockout disrupted the NADPH pool and increased reactive oxygen species (ROS) generation. Conversely, overexpression of GPER1 had the opposite effects. GPER1 suppressed nicotinamide adenine dinucleotide kinase 1(NADK1) ubiquitination and promoted its phosphorylation, which were responsible for the elevated expression of NADK1 at protein levels and activity, respectively. Moreover, genetic inhibition of NADK1 disrupted NADPH and redox homeostasis, leading to high levels of ROS and significant anoikis, which inhibited lung and peritoneal metastasis in cell‐based xenograft models. In summary, our study suggests that inhibiting GPER1‐mediated NADK1 activity and its ubiquitination may be a promising therapeutic strategy for peritoneal metastasis of gastric cancer.